Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/FASN_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FASN_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FASN_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FASN_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/FASN_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/FASN_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FASN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/FASN_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/FASN_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/FASN_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00067901 | Colorectum | SER | sulfur compound metabolic process | 73/2897 | 339/18723 | 1.75e-03 | 1.81e-02 | 73 |
GO:00300991 | Colorectum | SER | myeloid cell differentiation | 80/2897 | 381/18723 | 2.28e-03 | 2.18e-02 | 80 |
GO:00610281 | Colorectum | SER | establishment of endothelial barrier | 15/2897 | 46/18723 | 2.92e-03 | 2.59e-02 | 15 |
GO:00066621 | Colorectum | SER | glycerol ether metabolic process | 9/2897 | 22/18723 | 3.66e-03 | 3.06e-02 | 9 |
GO:00189041 | Colorectum | SER | ether metabolic process | 10/2897 | 27/18723 | 5.18e-03 | 3.95e-02 | 10 |
GO:00302241 | Colorectum | SER | monocyte differentiation | 12/2897 | 36/18723 | 6.11e-03 | 4.42e-02 | 12 |
GO:00066311 | Colorectum | SER | fatty acid metabolic process | 79/2897 | 390/18723 | 6.34e-03 | 4.56e-02 | 79 |
GO:00015031 | Colorectum | SER | ossification | 82/2897 | 408/18723 | 6.76e-03 | 4.78e-02 | 82 |
GO:00487322 | Colorectum | MSS | gland development | 143/3467 | 436/18723 | 3.85e-13 | 8.01e-11 | 143 |
GO:00061632 | Colorectum | MSS | purine nucleotide metabolic process | 128/3467 | 396/18723 | 2.04e-11 | 3.02e-09 | 128 |
GO:00091502 | Colorectum | MSS | purine ribonucleotide metabolic process | 121/3467 | 368/18723 | 2.08e-11 | 3.02e-09 | 121 |
GO:00725212 | Colorectum | MSS | purine-containing compound metabolic process | 132/3467 | 416/18723 | 4.13e-11 | 4.86e-09 | 132 |
GO:00020642 | Colorectum | MSS | epithelial cell development | 81/3467 | 220/18723 | 1.02e-10 | 1.06e-08 | 81 |
GO:00092592 | Colorectum | MSS | ribonucleotide metabolic process | 123/3467 | 385/18723 | 1.17e-10 | 1.20e-08 | 123 |
GO:00196932 | Colorectum | MSS | ribose phosphate metabolic process | 124/3467 | 396/18723 | 4.11e-10 | 3.49e-08 | 124 |
GO:00091172 | Colorectum | MSS | nucleotide metabolic process | 144/3467 | 489/18723 | 1.87e-09 | 1.35e-07 | 144 |
GO:00067532 | Colorectum | MSS | nucleoside phosphate metabolic process | 145/3467 | 497/18723 | 3.25e-09 | 2.23e-07 | 145 |
GO:00308792 | Colorectum | MSS | mammary gland development | 51/3467 | 137/18723 | 1.88e-07 | 8.26e-06 | 51 |
GO:00300992 | Colorectum | MSS | myeloid cell differentiation | 110/3467 | 381/18723 | 4.48e-07 | 1.75e-05 | 110 |
GO:00302242 | Colorectum | MSS | monocyte differentiation | 17/3467 | 36/18723 | 7.96e-05 | 1.32e-03 | 17 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FASN | SNV | Missense_Mutation | novel | c.2134T>A | p.Trp712Arg | p.W712R | P49327 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A3XS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
FASN | SNV | Missense_Mutation | rs771513967 | c.2635N>C | p.Thr879Pro | p.T879P | P49327 | protein_coding | tolerated(0.05) | benign(0.087) | TCGA-A7-A3IY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
FASN | SNV | Missense_Mutation | | c.6337N>A | p.Glu2113Lys | p.E2113K | P49327 | protein_coding | deleterious(0.02) | possibly_damaging(0.873) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FASN | SNV | Missense_Mutation | | c.5925N>C | p.Leu1975Phe | p.L1975F | P49327 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FASN | SNV | Missense_Mutation | | c.5531N>A | p.Ala1844Asp | p.A1844D | P49327 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FASN | SNV | Missense_Mutation | novel | c.5236N>G | p.Asn1746Asp | p.N1746D | P49327 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A2FE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
FASN | SNV | Missense_Mutation | rs759072039 | c.410N>A | p.Arg137Gln | p.R137Q | P49327 | protein_coding | deleterious(0.03) | possibly_damaging(0.664) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
FASN | SNV | Missense_Mutation | | c.5302N>A | p.Glu1768Lys | p.E1768K | P49327 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
FASN | SNV | Missense_Mutation | novel | c.4081N>G | p.Thr1361Ala | p.T1361A | P49327 | protein_coding | tolerated(0.13) | benign(0.08) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FASN | SNV | Missense_Mutation | | c.6665N>A | p.Leu2222Gln | p.L2222Q | P49327 | protein_coding | tolerated(0.18) | possibly_damaging(0.732) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | BI-87E7 | CHEMBL523200 | |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | GNF-PF-2262 | CHEMBL577862 | |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | GNF-PF-1307 | CHEMBL585030 | |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | TCMDC-124317 | CHEMBL586937 | |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | HEXACHLOROPHENE | HEXACHLOROPHENE | |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | Cerulenin | CERULENIN | |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | PACLITAXEL | PACLITAXEL | 15657900 |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | LORGLUMIDE SODIUM | LORGLUMIDE SODIUM | |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | FSA2 | | |
2194 | FASN | DRUGGABLE GENOME, ENZYME, SHORT CHAIN DEHYDROGENASE REDUCTASE | | PYROGALLOL RED | PYROGALLOL RED | |